Abstract

The enzyme γ-glutamyltranspeptidase 1 (GGT1) is a conserved member of the N-terminal nucleophile hydrolase family that cleaves the γ-glutamyl bond of glutathione and other γ-glutamyl compounds. In animals, GGT1 is expressed on the surface of the cell and has critical roles in maintaining cysteine levels in the body and regulating intracellular redox status. Expression of GGT1 has been implicated as a potentiator of asthma, cardiovascular disease, and cancer. The rational design of effective inhibitors of human GGT1 (hGGT1) has been delayed by the lack of a reliable structural model. The available crystal structures of several bacterial GGTs have been of limited use due to differences in the catalytic behavior of bacterial and mammalian GGTs. We report the high resolution (1.67 Å) crystal structure of glutamate-bound hGGT1, the first of any eukaryotic GGT. Comparisons of the active site architecture of hGGT1 with those of its bacterial orthologs highlight key differences in the residues responsible for substrate binding, including a bimodal switch in the orientation of the catalytic nucleophile (Thr-381) that is unique to the human enzyme. Compared with several bacterial counterparts, the lid loop in the crystal structure of hGGT1 adopts an open conformation that allows greater access to the active site. The hGGT1 structure also revealed tightly bound chlorides near the catalytic residue that may contribute to catalytic activity. These are absent in the bacterial GGTs. These differences between bacterial and mammalian GGTs and the new structural data will accelerate the development of new therapies for GGT1-dependent diseases.

Highlights

  • Human ␥-glutamyltranspeptidase 1 is a key enzyme in cysteine metabolism and several diseases

  • We have recently identified a novel class of uncompetitive species-specific human GGT1 (hGGT1) inhibitors that are several orders of magnitude less toxic than the canonical substrate analog, acivicin [15,16,17]

  • Structural Overview—The milligram quantities of hGGT1 required for crystallization made it impractical to purify the enzyme from human tissue, so we expressed a soluble form of hGGT1 in a yeast recombinant system

Read more

Summary

Background

Human ␥-glutamyltranspeptidase 1 (hGGT1) is a key enzyme in cysteine metabolism and several diseases. Strategic refinements of the structure of the founding member of this class of hGGT1 inhibitors, OU749, have been impeded by the lack of an accurate structural model for the human enzyme (or any eukaryotic GGT). Crystal structures have been reported for one archaeal (Thermoplasma acidophilum; PDB code 2i3o) and four bacterial (Escherichia coli, Helicobacter pylori, Bacillus subtilis, and Bacillus halodurans) GGTs [27,28,29] (PDB codes 2dbx, 2qm6, 3A75, and 2nlz, respectively) Among these structures, GGT from E. coli (EcGGT; P18956) has the highest amino acid sequence homology to hGGT1 (P19440), with 32% (172 of 533 residues) identity, 53% (280 of 533 residues) similarity, and 4% (20 of 533 residues) gaps (Fig. 1). This new information will serve as an essential launching point for the structure-based design of hGGT1 inhibitors with enhanced therapeutic efficacy

EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
CONCLUSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call